{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T17:43:56Z","timestamp":1790963036959,"version":"4.1.0"},"reference-count":31,"publisher":"Informa UK Limited","issue":"27","license":[{"start":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T00:00:00Z","timestamp":1762819200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"},{"start":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T00:00:00Z","timestamp":1762819200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/doi.org\/10.1080\/policies-text-data-mining"}],"funder":[{"DOI":"10.13039\/100004326","name":"Bayer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004326","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Future Oncology"],"published-print":{"date-parts":[[2025,11,14]]},"DOI":"10.1080\/14796694.2025.2577633","type":"journal-article","created":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T09:22:47Z","timestamp":1762852967000},"page":"3491-3498","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":4,"title":["Darolutamide plus androgen-deprivation therapy in high-risk biochemical recurrence of prostate cancer (ARASTEP)"],"prefix":"10.1080","volume":"21","author":[{"given":"Alicia K","family":"Morgans","sequence":"first","affiliation":[{"name":"Dana-Farber Cancer Institute","place":["Boston, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alex","family":"Chehrazi-Raffle","sequence":"additional","affiliation":[{"name":"City of Hope Comprehensive Cancer Center","place":["Duarte, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tamim","family":"Niazi","sequence":"additional","affiliation":[{"name":"Mcgill University","place":["Montreal, Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neal D","family":"Shore","sequence":"additional","affiliation":[{"name":"START carolinas\/Carolina Urologic Research Center","place":["Myrtle Beach, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashley E","family":"Ross","sequence":"additional","affiliation":[{"name":"Northwestern University Feinberg School of Medicine","place":["Chicago, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"R\u00f8der","sequence":"additional","affiliation":[{"name":"University of Copenhagen","place":["Copenhagen, Denmark"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea Juliana","family":"Gomes","sequence":"additional","affiliation":[{"name":"Liga Norte Riograndense Contra O Cancer","place":["Natal, Brazil"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephane","family":"Supiot","sequence":"additional","affiliation":[{"name":"Institut de Canc\u00e9rologie de l\u2019Ouest","place":["Saint-Herblain, France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Barth\u00e9l\u00e9my","sequence":"additional","affiliation":[{"name":"University Hospital of Strasbourg","place":["Strasbourg, France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koji","family":"Hatano","sequence":"additional","affiliation":[{"name":"The University of Osaka","place":["Osaka, Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmen Belen Congregado","family":"Ruiz","sequence":"additional","affiliation":[{"name":"Virgen Del Roc\u00edo University Hospital","place":["Seville, Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soichiro","family":"Yoshida","sequence":"additional","affiliation":[{"name":"Institute of Science Tokyo","place":["Tokyo, Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernardo","family":"Herrera-Imbroda","sequence":"additional","affiliation":[{"name":"Urology Unit, ibima-Plataforma Bionand","place":["Malaga, Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthieu","family":"Gratton","sequence":"additional","affiliation":[{"name":"H\u00f4pital H\u00f4tel-Dieu de L\u00e9vis","place":["L\u00e9vis, Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00fcrgen E","family":"Gschwend","sequence":"additional","affiliation":[{"name":"Technical University Munich","place":["Munich, Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas A","family":"Hope","sequence":"additional","affiliation":[{"name":"University of San Francisco","place":["San Francisco, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heikki","family":"Joensuu","sequence":"additional","affiliation":[{"name":"Orion Pharma","place":["Espoo, Finland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iris","family":"Kuss","sequence":"additional","affiliation":[{"name":"Bayer AG","place":["Berlin, Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie-Aude","family":"Le Berre","sequence":"additional","affiliation":[{"name":"Bayer Healthcare SAS","place":["Lille, France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miryana","family":"Dimova-Dobreva","sequence":"additional","affiliation":[{"name":"Bayer Consumer Care AG","place":["Basel, Switzerland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6068-9474","authenticated-orcid":false,"given":"Karim","family":"Fizazi","sequence":"additional","affiliation":[{"name":"University of Paris-Saclay","place":["Villejuif, France"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2025,11,11]]},"reference":[{"key":"e_1_3_9_3_1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21820"},{"key":"e_1_3_9_4_1","unstructured":"Globocan. Absolute numbers incidence males in 2022. 2022 [cited 2024 Nov 6]. Available from: https:\/\/gco.iarc.fr\/today\/en\/dataviz\/pie?mode=cancer&group_populations=1&sexes=1&populations=900"},{"key":"e_1_3_9_5_1","unstructured":"Cornford P Tilki D van den Bergh RCN et al. EAU-EANM-ESTRO-ESUR-ISUP-SIOG guidelines on prostate cancer 2024. [2024 Sep 20]. Available from: https:\/\/uroweb.org\/guideline\/prostate-cancer\/"},{"key":"e_1_3_9_6_1","doi-asserted-by":"publisher","DOI":"10.1590\/s1677-5538.ibju.2016.0656"},{"issue":"1","key":"e_1_3_9_7_1","first-page":"14","article-title":"Management of biochemically recurrent prostate cancer after local therapy: evolving standards of care and new directions","volume":"11","author":"Paller CJ","year":"2013","unstructured":"Paller CJ, Antonarakis ES. Management of biochemically recurrent prostate cancer after local therapy: evolving standards of care and new directions. Clin Adv Hematol Oncol. 2013 Jan;11(1):14\u201323.","journal-title":"Clin Adv Hematol Oncol"},{"key":"e_1_3_9_8_1","doi-asserted-by":"publisher","DOI":"10.1159\/000481438"},{"key":"e_1_3_9_9_1","doi-asserted-by":"publisher","DOI":"10.3892\/ijo.2019.4893"},{"key":"e_1_3_9_10_1","doi-asserted-by":"publisher","DOI":"10.3390\/diagnostics12112594"},{"key":"e_1_3_9_11_1","doi-asserted-by":"publisher","DOI":"10.2214\/AJR.20.23912"},{"key":"e_1_3_9_12_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11864-024-01181-9"},{"key":"e_1_3_9_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clgc.2019.08.002"},{"key":"e_1_3_9_14_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14174078"},{"key":"e_1_3_9_15_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15010247"},{"key":"e_1_3_9_16_1","doi-asserted-by":"publisher","DOI":"10.1097\/JU.0000000000003452"},{"key":"e_1_3_9_17_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.03256"},{"key":"e_1_3_9_18_1","doi-asserted-by":"publisher","DOI":"10.1155\/2022\/5454727"},{"key":"e_1_3_9_19_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2303974"},{"key":"e_1_3_9_20_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1815671"},{"key":"e_1_3_9_21_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2001342"},{"key":"e_1_3_9_22_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2119115"},{"key":"e_1_3_9_23_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2022.40.6_suppl.013"},{"key":"e_1_3_9_24_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO-24-01798"},{"key":"e_1_3_9_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2023.09.2789"},{"issue":"16","key":"e_1_3_9_26_1","article-title":"Darolutamide plus androgen-deprivation therapy (ADT) in patients with high-risk biochemical recurrence (BCR) of prostate cancer: a phase III, randomized, double-blind, placebo-controlled study (ARASTEP)","volume":"43","author":"Morgans AK","year":"2025","unstructured":"Morgans AK, Niazi T, Shore ND, et al. Darolutamide plus androgen-deprivation therapy (ADT) in patients with high-risk biochemical recurrence (BCR) of prostate cancer: a phase III, randomized, double-blind, placebo-controlled study (ARASTEP). J Clin Oncol. 2025 May 28;43(16):Number 16_suppl.","journal-title":"J Clin Oncol"},{"key":"e_1_3_9_27_1","article-title":"Darolutamide plus androgen-deprivation therapy (ADT) in patients with high-risk biochemical recurrence (BCR) of prostate cancer: a phase III, randomized, double-blind, placebo-controlled study (ARASTEP)","volume":"43","author":"Morgans AK","year":"2025","unstructured":"Morgans AK, Niazi T, Shore ND, et al. Darolutamide plus androgen-deprivation therapy (ADT) in patients with high-risk biochemical recurrence (BCR) of prostate cancer: a phase III, randomized, double-blind, placebo-controlled study (ARASTEP). J Clin Oncol. 2025 Feb 18;43:Number 5 _suppl.","journal-title":"J Clin Oncol"},{"issue":"5","key":"e_1_3_9_28_1","first-page":"e27","article-title":"Darolutamide plus androgen-deprivation therapy (ADT) in patients with high-risk biochemical recurrence (BCR) of prostate cancer: a phase III, randomized, double-blind, placebo-controlled study (ARASTEP)","volume":"213","author":"Shore N","year":"2025","unstructured":"Shore N, Fizazi K, Niazi T, et al. Darolutamide plus androgen-deprivation therapy (ADT) in patients with high-risk biochemical recurrence (BCR) of prostate cancer: a phase III, randomized, double-blind, placebo-controlled study (ARASTEP). J Urol. 2025 May;213(5S2):e27\u201328.","journal-title":"J Urol"},{"key":"e_1_3_9_29_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.23.01157"},{"key":"e_1_3_9_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(24)00549-X"},{"key":"e_1_3_9_31_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2024.29783"},{"key":"e_1_3_9_32_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.euf.2019.06.004"},{"key":"e_1_3_9_33_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2023.02.018"}],"container-title":["Future Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/14796694.2025.2577633","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.tandfonline.com\/doi\/full-xml\/10.1080\/14796694.2025.2577633","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/14796694.2025.2577633","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T05:53:53Z","timestamp":1787896433000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/14796694.2025.2577633"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,11]]},"references-count":31,"journal-issue":{"issue":"27","published-print":{"date-parts":[[2025,11,14]]}},"alternative-id":["10.1080\/14796694.2025.2577633"],"URL":"https:\/\/doi.org\/10.1080\/14796694.2025.2577633","relation":{},"ISSN":["1479-6694","1744-8301"],"issn-type":[{"value":"1479-6694","type":"print"},{"value":"1744-8301","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,11]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ifon20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ifon20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2025-07-25","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-10-16","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-11-11","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}